DB19433ExperimentalCell transplant therapies
DT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.
- Also known as
- Dystrophin Expressing Chimeric Cells derived from allogenic normal human myoblast and autologous DMD myoblast from Duchenne muscular dystrophy affected donor
- Code names
- DT-DEC01
Which companies are running trials of DT-DEC01, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account